- Home
- AVD vs ZNTL Comparison
AVD vs ZNTL Comparison
Compare AVD & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVD | ZNTL |
|---|---|---|
| Founded | 1969 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.4M | 162.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | AVD | ZNTL |
|---|---|---|
| Price | $5.27 | $2.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $12.00 | $6.60 |
| AVG Volume (30 Days) | 187.8K | ★ 679.9K |
| Earning Date | 03-13-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $530,073,000.00 | $26,865,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.28 | $1.01 |
| 52 Week High | $5.92 | $3.95 |
Technical Indicators
Market Signals| Indicator | AVD | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 68.94 | 47.63 |
| Support Level | $4.95 | $2.26 |
| Resistance Level | $5.32 | $2.51 |
| Average True Range (ATR) | 0.21 | 0.24 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 79.73 | 18.99 |
Price Performance
Historical ComparisonAbout AVD American Vanguard Corporation ($0.10 Par Value)
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. It manufactures and formulates chemicals for crops, turf and ornamental plants, and human and animal health protection. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.